GRANOCYTE

This brand name is authorized in Cyprus, Finland, France, Ireland, Lithuania, Malta, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug GRANOCYTE contains one active pharmaceutical ingredient (API):

1	Lenograstim UNII 6WS4C399GB - LENOGRASTIM
	Lenograstim belongs to the cytokine group of biologically active proteins which regulate cell differentiation and cell growth. Lenograstim induces a marked increase in peripheral blood neutrophil counts within 24 hours of administration.
	Read more about Lenograstim

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
GRANOCYTE Powder and solvent for solution for injection/infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L03AA10	Lenograstim	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AA Colony stimulating factors
Discover more medicines within L03AA10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
ES	Centro de información online de medicamentos de la AEMPS	60211, 60672
FI	Lääkealan turvallisuus- ja kehittämiskeskus	552799
FR	Base de données publique des médicaments	63992157, 65066667, 66807418, 68179481, 69826879
GB	Medicines & Healthcare Products Regulatory Agency	356093, 356094, 356098, 356099
IE	Health Products Regulatory Authority	88075, 88076
LT	Valstybinė vaistų kontrolės tarnyba	1015343, 1026447, 1036078, 1036079
MT	Medicines Authority	AA565/94901
SG	Health Sciences Authority	09427P
TN	Direction de la Pharmacie et du Médicament	18943011H, 8613011H
TR	İlaç ve Tıbbi Cihaz Kurumu	8699586792090
ZA	Health Products Regulatory Authority	31/30.4/0074, 31/30.4/0075